Oral small molecule GLP-1 receptor agonist
Lotiglipron 20 mg tablet once daily
LOTI_PO_20MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.14 (0.00 to 1.89) | 0.85 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.89 (0.20 to 2.95) | 0.67 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.24 (0.97 to 4.99) | 0.56 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.50 (0.04 to 2.73) | 0.83 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.48 (0.61 to 3.40) | 0.53 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.65 (0.11 to 2.58) | 0.74 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.93 (0.06 to 16.27) | 0.45 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.59 (0.01 to 23.73) | 0.53 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.14 (0.00 to 2.14) | 0.85 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.79 (0.16 to 2.92) | 0.72 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.67 (0.71 to 3.84) | 0.79 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.44 (0.04 to 2.57) | 0.93 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.11 (0.40 to 2.72) | 0.72 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.49 (0.08 to 2.10) | 0.85 |